|
1
|
Chu KF and Dupuy DE: Thermal ablation of
tumours: Biological mechanisms and advances in therapy. Nat Rev
Cancer. 14:199–208. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Robinson RD and Knudtson JF: Fertility
preservation in patients receiving chemotherapy or radiotherapy. Mo
Med. 111:434–438. 2014.
|
|
3
|
Killion JJ and Fidler IJ: Therapy of
cancer metastasis by tumoricidal activation of tissue macrophages
using liposome-encapsulated immunomodulators. Pharmacol Ther.
78:141–154. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sheridan C: Industry pursues
co-stimulatory receptor immunomodulators to treat cancer. Nat
Biotechnol. 31:181–183. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Berinstein NL: Enhancing cancer vaccines
with immunomodulators. Vaccine. 25:(Suppl 2). B72–B88. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yun TK: Brief introduction of Panax
ginseng C.A. Meyer. J Korean Med Sci. 16:Suppl. S3–S5. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu H, Chen J, Wang Q, Jia X, Song S, Yuan
P, Liu K, Liu L, Zhang Y, Zhou A and Wei W: Ginsenoside metabolite
compound K attenuates inflammatory responses of adjuvant-induced
arthritis rats. Immunopharmacol Immunotoxicol. 36:124–129. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu KK, Wang QT, Yang SM, Chen JY, Wu HX
and Wei W: Ginsenoside compound K suppresses the abnormal
activation of T lymphocytes in mice with collagen-induced
arthritis. Acta Pharmacol Sin. 35:599–612. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen J, Wu H, Wang Q, Chang Y, Liu K, Song
S, Yuan P, Fu J, Sun W, Huang Q, et al: Ginsenoside metabolite
compound k alleviates adjuvant-induced arthritis by suppressing T
cell activation. Inflammation. 37:1608–1615. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Q, Hong B, Wu S and Niu T:
Inhibition of prostatic cancer growth by ginsenoside Rh2. Tumour
Biol. 36:2377–2381. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi Q, Li J, Feng Z, Zhao L, Luo L, You Z,
Li D, Xia J, Zuo G and Chen D: Effect of ginsenoside Rh2 on the
migratory ability of HepG2 liver carcinoma cells: Recruiting
histone deacetylase and inhibiting activator protein 1
transcription factors. Mol Med Rep. 10:1779–1785. 2014.PubMed/NCBI
|
|
12
|
Tang XP, Tang GD, Fang CY, Liang ZH and
Zhang LY: Effects of ginsenoside Rh2 on growth and migration of
pancreatic cancer cells. World J Gastroenterol. 19:1582–1592. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou DB, Hu CP, Liang S and Yang HZ:
Effect of ginsenoside Rh2 on immunocompetence of alveolar
macrophages in patients with non-small cell lung cancer. Zhong Nan
Da Xue Xue Bao Yi Xue Ban. 32:868–872. 2007.(In Chinese).
PubMed/NCBI
|
|
14
|
Wu R, Ru Q, Chen L, Ma B and Li C:
Stereospecificity of ginsenoside Rg3 in the promotion of cellular
immunity in hepatoma H22-bearing mice. J Food Sci. 79:H1430–H1435.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Waitz R, Solomon SB, Petre EN, Trumble AE,
Fassò M, Norton L and Allison JP: Potent induction of tumor
immunity by combining tumor cryoablation with anti-CTLA-4 therapy.
Cancer Res. 72:430–439. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li F, Guo Z, Yu H, Zhang X, Si T, Liu C,
Yang X and Qi L: Anti-tumor immunological response induced by
cryoablation and anti-CTLA-4 antibody in an in vivo RM-1 cell
prostate cancer murine model. Neoplasma. 61:659–671. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kvistborg P, Philips D, Kelderman S,
Hageman L, Ottensmeier C, Joseph-Pietras D, Welters MJ, van der
Burg S, Kapiteijn E, Michielin O, et al: Anti-CTLA-4 therapy
broadens the melanoma-reactive CD8+ T cell response. Sci
Transl Med. 6:254ra128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao Q, Tong L, He N, Feng G, Leng L, Sun
W, Xu Y, Wang Y, Xiang R and Li Z: IFN-gamma mediates
graft-versus-breast cancer effects via enhancing cytotoxic T
lymphocyte activity. Exp Ther Med. 8:347–354. 2014.PubMed/NCBI
|
|
19
|
Gu Y, Wang GJ, Sun JG, Jia YW, Wang W, Xu
MJ, Lv T, Zheng YT and Sai Y: Pharmacokinetic characterization of
ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and
dogs. Food Chem Toxicol. 47:2257–2268. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li S, Guo W, Gao Y and Liu Y: Ginsenoside
Rh2 inhibits growth of glioblastoma multiforme through mTor. Tumour
Biol. 36:6207–2612. 2015.
|
|
21
|
Li B, Zhao J, Wang CZ, Searle J, He TC,
Yuan CS and Du W: Ginsenoside Rh2 induces apoptosis and
paraptosis-like cell death in colorectal cancer cells through
activation of p53. Cancer Lett. 301:185–192. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee JH and Han Y: Ginsenoside Rg1 helps
mice resist to disseminated candidiasis by Th1 type differentiation
of CD4+ T cell. Int Immunopharmacol. 6:1424–1430. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee EJ, Ko E, Lee J, Rho S, Ko S, Shin MK,
Min BI, Hong MC, Kim SY and Bae H: Ginsenoside Rg1 enhances CD4(+)
T-cell activities and modulates Th1/Th2 differentiation. Int
ImmunoPharmacol. 4:235–244. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang Z, Chen A, Sun H, Ye Y and Fang W:
Ginsenoside Rd elicits Th1 and Th2 immune responses to ovalbumin in
mice. Vaccine. 25:161–169. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Y, Liu Y, Zhang XY, Xu LH, Ouyang DY,
Liu KP, Pan H, He J and He XH: Ginsenoside Rg1 regulates innate
immune responses in macrophages through differentially modulating
the NF-κB and PI3K/Akt/mTOR pathways. Int Immunopharmacol.
23:77–84. 2014. View Article : Google Scholar : PubMed/NCBI
|
